1.42
price down icon3.40%   -0.05
pre-market  Pre-market:  1.41   -0.01   -0.70%
loading

Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News

pulisher
Feb 05, 2025

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 - GlobeNewswire Inc.

Feb 05, 2025
pulisher
Jan 14, 2025

USC Law Launches New Online Certificate in Dispute Resolution - Business Wire

Jan 14, 2025
pulisher
Jan 10, 2025

Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions - Business Wire

Jan 10, 2025
pulisher
Dec 07, 2024

Cronos Group Inc (NASDAQ: CRON) Could Slash -12.75% Soon - Stocks Register

Dec 07, 2024
pulisher
Dec 07, 2024

Commercial Metals Co (NYSE: CMC) Could Slash -1.03% Soon - Stocks Register

Dec 07, 2024
pulisher
Dec 05, 2024

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Reckitt Benckiser Group PLC (OTC: RBGLY) - Business Wire

Dec 05, 2024
pulisher
Dec 04, 2024

Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com India

Dec 04, 2024
pulisher
Nov 04, 2024

Can-Fite secures Australian patent for obesity treatment - Investing.com

Nov 04, 2024
pulisher
Oct 28, 2024

Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of WeRide Inc. - Business Wire

Oct 28, 2024
pulisher
Oct 18, 2024

Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India

Oct 18, 2024
pulisher
Sep 25, 2024

Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 25, 2024
pulisher
Sep 24, 2024

What is CANF’s price-to-sales ratio telling us about the company’s value? - US Post News

Sep 24, 2024
pulisher
Sep 02, 2024

Taking on analysts’ expectations and winning: Can-Fite Biopharma Ltd ADR (CANF) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

CANF (Can-Fite Biopharma Ltd ADR) has impressive results - US Post News

Sep 02, 2024
pulisher
Aug 26, 2024

List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel

Aug 26, 2024
pulisher
Aug 23, 2024

Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com

Aug 23, 2024
pulisher
Nov 21, 2023

symbol__ Stock Quote Price and Forecast - CNN

Nov 21, 2023
pulisher
Jul 12, 2023

Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK

Jul 12, 2023
pulisher
Dec 30, 2022

Can-Fite Announces ADS Ratio Change - Business Wire

Dec 30, 2022
pulisher
Oct 19, 2022

Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici

Oct 19, 2022
pulisher
Feb 01, 2022

NOVONIX to Commence Trading on Nasdaq through Level II ADR Program - Business Wire

Feb 01, 2022
pulisher
Mar 16, 2021

Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire

Mar 16, 2021
pulisher
Sep 16, 2020

Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat

Sep 16, 2020
pulisher
Jul 15, 2020

New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire

Jul 15, 2020
pulisher
Feb 19, 2020

Global Metal Casting Market 2020-2024 | Evolving Opportunities with Acast and Alcast Co. | Technavio - Business Wire

Feb 19, 2020
pulisher
Aug 24, 2019

10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance

Aug 24, 2019
pulisher
Aug 02, 2016

Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha

Aug 02, 2016
pulisher
Sep 03, 2015

letgo Raises $100 Million in Series A Funding from Naspers - Business Wire

Sep 03, 2015
pulisher
Oct 04, 2012

Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC

Oct 04, 2012
$80.78
price down icon 0.82%
$20.67
price down icon 0.53%
$353.75
price down icon 0.12%
$5.04
price down icon 2.14%
biotechnology ONC
$228.87
price up icon 0.53%
$119.94
price down icon 1.99%
Cap:     |  Volume (24h):